Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN) +++ IOVANCE Aktie -3,01%

TG THERAPEUTICS Aktie

 >TG THERAPEUTICS Aktienkurs 
31.585 EUR    +1.0%    (Tradegate)
Ask: 31.745 EUR / 60 Stück
Bid: 31.43 EUR / 60 Stück
Tagesumsatz: 10 Stück
Realtime Kurs von 8 bis 22 Uhr!
TG THERA Aktie über LYNX handeln
>TG THERAPEUTICS Performance
1 Woche: +3,1%
1 Monat: +5,1%
3 Monate: -19,9%
6 Monate: +0,6%
1 Jahr: +92,5%
laufendes Jahr: +2,6%
>TG THERAPEUTICS Aktie
Name:  TG THERAPEUTICS DL -,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US88322Q1085 / A1JXW7
Symbol/ Ticker:  NKB2 (Frankfurt) / TGTX (NASDAQ)
Kürzel:  FRA:NKB2, ETR:NKB2, NKB2:GR, NASDAQ:TGTX
Index:  -
Webseite:  http://www.tgtherapeutics..
Marktkapitalisierung:  4930 Mio. EUR
Umsatz:  333.61 Mio. EUR
EBITDA:  51.69 Mio. EUR
Gewinn je Aktie:  0.19 EUR
Schulden:  219.8 Mio. EUR
Liquide Mittel:  238.5 Mio. EUR
Umsatz-/ Gewinnwachstum:  90.4% / -
KGV/ KGV lG:  147.93 / 26.6
KUV/ KBV/ PEG:  15.74 / 24.74 / -
Gewinnm./ Eigenkapitalr.:  10.13% / 19.7%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 369.400 USD.
Suchwörter:  TG THERAPEUTICS, TG THERAPEUTIC, TG THERA
Letzte Datenerhebung:  23.06.25
>TG THERA Eigentümer
Aktien: 158.76 Mio. St.
f.h. Aktien: 135.13 Mio. St.
Insider Eigner: 9.7%
Instit. Eigner: 63.24%
>TG THERA Peer Group

 
17.06.25 - 04:01
Insiderhandel: Aufsichtsrat verkauft Aktien von TG Therapeutics im Wert von 369400 USD (Insiderkauf)
 
Echelard, Yann - Aufsichtsrat - Tag der Transaktion: 2025-06-13...
16.06.25 - 17:30
Are Options Traders Betting on a Big Move in TG Therapeutics Stock? (Zacks)
 
Investors need to pay close attention to TGTX stock based on the movements in the options market lately....
06.06.25 - 13:33
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire EN)
 
Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET....
30.05.25 - 13:33
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire EN)
 
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below....
27.05.25 - 13:33
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire EN)
 
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC meeting website at www.mscare.org/2025. Details of the upcoming presentations are outlined below....
05.05.25 - 21:48
Why TG Therapeutics Stock Was Tumbling Today (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 18:18
TG Therapeutics stock sinks on profit miss (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 17:00
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 16:00
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates (Zacks)
 
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
05.05.25 - 13:06
TG Therapeutics GAAP EPS of $0.03 misses by $0.14, revenue of $120.86M beats by $3M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 13:03
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance (GlobeNewswire EN)
 
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million...
02.05.25 - 20:03
TG Therapeutics Q1 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.25 - 17:30
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
 
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
30.04.25 - 13:33
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update (GlobeNewswire EN)
 
Conference call to be held Monday, May 5, 2025, at 8:30 AM ET Conference call to be held Monday, May 5, 2025, at 8:30 AM ET...
10.04.25 - 19:45
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here′s Why (Zacks)
 
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line....
10.04.25 - 13:33
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire EN)
 
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below....
08.04.25 - 13:33
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire EN)
 
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below....
07.04.25 - 13:33
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals (GlobeNewswire EN)
 
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below....
02.04.25 - 18:21
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.03.25 - 12:00
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? (Zacks)
 
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!